These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 22851406)

  • 21. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.
    Dranitsaris G; Hatzimichael E
    Support Care Cancer; 2012 Jul; 20(7):1353-60. PubMed ID: 22539050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G
    Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
    [No Abstract]   [Full Text] [Related]  

  • 24. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
    Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
    Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
    Hechmati G; Hauber AB; Arellano J; Mohamed AF; Qian Y; Gatta F; Haynes I; Bahl A; von Moos R; Body JJ
    Support Care Cancer; 2015 Jan; 23(1):21-8. PubMed ID: 24939674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
    Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
    Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
    Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
    Saad F
    Clin Prostate Cancer; 2005 Jun; 4(1):31-7. PubMed ID: 15992459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
    Ford J; Cummins E; Sharma P; Elders A; Stewart F; Johnston R; Royle P; Jones R; Mulatero C; Todd R; Mowatt G
    Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
    Body JJ; Gatta F; De Cock E; Tao S; Kritikou P; Wimberger P; Mebis J; Peeters M; Pedrazzoli P; Caraceni A; Adamo V; Hechmati G
    Support Care Cancer; 2017 Sep; 25(9):2823-2832. PubMed ID: 28429148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.
    Chen J; Zhou L; Liu X; Wen X; Li H; Li W
    Int J Clin Pharm; 2021 Feb; 43(1):2-10. PubMed ID: 32964403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
    Huang SY; Yoon SS; Shimizu K; Chng WJ; Chang CS; Wong RS; Gao S; Wang Y; Gordon SW; Glennane A; Min CK
    Adv Ther; 2020 Jul; 37(7):3404-3416. PubMed ID: 32524500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.